{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:56:28Z","timestamp":1740149788801,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s12288-022-01599-x","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T22:02:38Z","timestamp":1668031358000},"page":"487-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bendamustine-Rituximab in Young CLL: Relevance in the Era of Small Molecule Inhibitors"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8461-6950","authenticated-orcid":false,"given":"Sukrita","family":"Bhattacharjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2804-7815","authenticated-orcid":false,"given":"Shouriyo","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1437-0216","authenticated-orcid":false,"given":"Maitreyee","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"1599_CR1","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA et al (2018) Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 379:2517\u20132528","journal-title":"N Engl J Med"},{"key":"1599_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE et al (2019) Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 381:432\u2013443","journal-title":"N Engl J Med"},{"key":"1599_CR3","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J et al (2019) Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 380:2225\u20132236","journal-title":"N Engl J Med"},{"issue":"10232","key":"1599_CR4","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW et al (2020) Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 395(10232):1278\u201391","journal-title":"Lancet"},{"key":"1599_CR5","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/j.1365-2141.2008.07226.x","volume":"142","author":"C Gunawardana","year":"2008","unstructured":"Gunawardana C, Austen B, Powell JE et al (2008) South Asian chronic lymphocytic leukaemia patients have more rapid disease progression in comparison to white patients. Br J Haematol 142:606\u2013609","journal-title":"Br J Haematol"},{"key":"1599_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/10245330701255064","volume":"12","author":"N Agrawal","year":"2007","unstructured":"Agrawal N, Naithani R, Mahapatra M et al (2007) Chronic lymphocytic leukemia in India\u2013a clinico-hematological profile. Hematology 12:229\u2013233","journal-title":"Hematology"},{"issue":"11","key":"1599_CR7","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1002\/ajh.25595","volume":"94","author":"M Hallek","year":"2019","unstructured":"Hallek M (2019) Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol 94(11):1266\u20131287. https:\/\/doi.org\/10.1002\/ajh.25595","journal-title":"Am J Hematol"},{"issue":"25","key":"1599_CR8","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131(25):2745\u20132760","journal-title":"Blood"},{"issue":"7","key":"1599_CR9","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C et al (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17(7):928\u2013942","journal-title":"Lancet Oncol"},{"key":"1599_CR10","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1200\/GO.20.00032","volume":"6","author":"V Tejaswi","year":"2020","unstructured":"Tejaswi V, Lad DP, Jindal N et al (2020) Chronic lymphocytic leukemia: real-world data from India. JCO Glob Oncol 6:866\u2013872. https:\/\/doi.org\/10.1200\/GO.20.00032","journal-title":"JCO Glob Oncol"},{"issue":"1","key":"1599_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bjh.12000","volume":"159","author":"WU Knauf","year":"2012","unstructured":"Knauf WU, Lissitchkov T, Aldaoud A, Liberati AM, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Merkle K, Montillo M (2012) Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol 159(1):67\u201377. https:\/\/doi.org\/10.1111\/bjh.12000","journal-title":"Br J Haematol"},{"key":"1599_CR12","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/GO.20.00012","volume":"6","author":"V Sathyanarayanan","year":"2020","unstructured":"Sathyanarayanan V, Flowers CR, Iyer SP (2020) Comparison of access to novel drugs for lymphoma and chronic lymphocytic leukemia between India and the United States. JCO Glob Oncol 6:1124\u20131133. https:\/\/doi.org\/10.1200\/GO.20.00012","journal-title":"JCO Glob Oncol"},{"issue":"3","key":"1599_CR13","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/jha2.227","volume":"2","author":"N Sood","year":"2021","unstructured":"Sood N, Varghese A, Chakrabarty J, Chezhian S, Sopory P (2021) Acalabrutinib in management of chronic lymphocytic leukemia: an Indian perspective. eJHaem 2(3):628\u2013634. https:\/\/doi.org\/10.1002\/jha2.227","journal-title":"eJHaem"},{"issue":"4","key":"1599_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.4103\/ijmpo.ijmpo_43_17","volume":"38","author":"MB Agarwal","year":"2017","unstructured":"Agarwal MB, Bhurani D, Shah C et al (2017) Efficacy and safety of Ibrutinib in Indian patients with relapsed or refractory chronic lymphocytic Leukemia and mantle cell lymphoma: cases from a named patient program. Indian J Med Paediatr Oncol 38(4):508\u2013515. https:\/\/doi.org\/10.4103\/ijmpo.ijmpo_43_17","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"2","key":"1599_CR15","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s12288-018-1011-4","volume":"35","author":"DP Lad","year":"2019","unstructured":"Lad DP, Malhotra P, Khadwal A, Prakash G, Jain A, Varma S (2019) Reduced Dose Ibrutinib Due to Financial Toxicity in CLL. Indian J Hematol Blood Transfus. 35(2):260\u2013264. https:\/\/doi.org\/10.1007\/s12288-018-1011-4","journal-title":"Indian J Hematol Blood Transfus."}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-022-01599-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-022-01599-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-022-01599-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T06:40:08Z","timestamp":1686120008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-022-01599-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1599"],"URL":"https:\/\/doi.org\/10.1007\/s12288-022-01599-x","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"type":"print","value":"0971-4502"},{"type":"electronic","value":"0974-0449"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"20 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Yes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Retrospective study, IEC number: (MC\/KOL\/IEC\/NON-SPON\/963\/03\/2021).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}